Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mobile Applications | 2 | 2025 | 110 | 0.370 |
Why?
|
| Self-Management | 2 | 2025 | 113 | 0.370 |
Why?
|
| Asthma | 2 | 2025 | 909 | 0.230 |
Why?
|
| Cancer Vaccines | 1 | 2025 | 190 | 0.210 |
Why?
|
| Dendritic Cells | 1 | 2025 | 435 | 0.190 |
Why?
|
| Atrial Septum | 1 | 2022 | 19 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2025 | 379 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 299 | 0.150 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2022 | 268 | 0.140 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 21 | 0.140 |
Why?
|
| Febuxostat | 1 | 2018 | 21 | 0.140 |
Why?
|
| Azithromycin | 1 | 2018 | 46 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 564 | 0.130 |
Why?
|
| Allopurinol | 1 | 2018 | 79 | 0.130 |
Why?
|
| Medicine | 1 | 2018 | 100 | 0.120 |
Why?
|
| Veterans Health | 1 | 2018 | 171 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2022 | 805 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 229 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1350 | 0.120 |
Why?
|
| Gout | 1 | 2018 | 172 | 0.110 |
Why?
|
| Meningitis, Bacterial | 1 | 2015 | 98 | 0.100 |
Why?
|
| Sulfasalazine | 1 | 2013 | 4 | 0.100 |
Why?
|
| Hydroxychloroquine | 1 | 2013 | 19 | 0.100 |
Why?
|
| Pneumococcal Vaccines | 1 | 2015 | 174 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 72 | 0.100 |
Why?
|
| Pneumococcal Infections | 1 | 2015 | 279 | 0.090 |
Why?
|
| Antirheumatic Agents | 1 | 2013 | 119 | 0.090 |
Why?
|
| Methotrexate | 1 | 2013 | 336 | 0.080 |
Why?
|
| Bacteremia | 1 | 2015 | 425 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 790 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 283 | 0.080 |
Why?
|
| Middle Aged | 7 | 2025 | 28395 | 0.060 |
Why?
|
| Adult | 7 | 2025 | 31125 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2546 | 0.060 |
Why?
|
| Mycobacterium ulcerans | 1 | 2005 | 3 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1250 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2005 | 32 | 0.060 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2005 | 46 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12852 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 219 | 0.050 |
Why?
|
| Male | 8 | 2025 | 64486 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 398 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 36 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 1625 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2025 | 1501 | 0.040 |
Why?
|
| Young Adult | 3 | 2025 | 9974 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8525 | 0.040 |
Why?
|
| Aged | 4 | 2025 | 20899 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 259 | 0.040 |
Why?
|
| Humans | 10 | 2025 | 130403 | 0.040 |
Why?
|
| Female | 7 | 2025 | 70343 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 372 | 0.040 |
Why?
|
| Telemedicine | 1 | 2025 | 511 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 499 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 21 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 22 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 6773 | 0.030 |
Why?
|
| Uric Acid | 1 | 2018 | 110 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2018 | 75 | 0.030 |
Why?
|
| United States | 3 | 2018 | 11826 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 684 | 0.030 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 87 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5204 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2923 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 286 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1610 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 718 | 0.030 |
Why?
|
| Infant | 3 | 2018 | 13276 | 0.030 |
Why?
|
| Etanercept | 1 | 2013 | 44 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2018 | 14982 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 351 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 769 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1292 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 20731 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1163 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2022 | 3105 | 0.020 |
Why?
|
| Child | 3 | 2018 | 26159 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 3346 | 0.020 |
Why?
|
| Ghana | 1 | 2005 | 22 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 3030 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17633 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 323 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 1224 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1380 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 3408 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 10981 | 0.010 |
Why?
|